Nephrology

SGLT inhibitors have changed the treatment landscape for cardiovascular and kidney disease, particularly in people with type 2 diabetes, heart failure, and chronic kidney disease. That success raises an obvious question: why are SGLT inhibitors in type 1 diabetes still largely outside routine clinical practice? The answer is not a …

Managing glucose is rarely simple for people with Type 2 diabetes who receive maintenance hemodialysis. Dialysis can change glucose patterns, insulin needs, and the reliability of familiar measures such as A1C. As a result, clinicians may have an incomplete picture when making treatment decisions. New randomized research on CGM use …

For people with diabetes, a retinal photograph has traditionally answered one major question: Is diabetic retinopathy developing? However, artificial intelligence is beginning to uncover much more. Emerging retinal AI models for systemic risk assessment can detect patterns associated with cardiovascular disease, kidney disease, blood pressure, and metabolic health. As a …

Artificial intelligence is rapidly changing how healthcare professionals diagnose disease. But can computers identify kidney damage before it becomes obvious under a microscope? Researchers believe the answer may be yes. The combination of digital pathology, artificial intelligence, and diabetic kidney disease research is opening new opportunities to identify microscopic kidney …

Early detection has always been one of the biggest challenges in diabetes care. What if doctors could identify patients at high risk for diabetic neuropathy or kidney disease years before symptoms developed? That possibility is driving exciting new research into IgG glycosylation in diabetes, an emerging area that examines subtle …

Diabetes is known for raising blood sugar levels, but its long-term complications often have the greatest impact on health. Kidney disease, vision loss, nerve damage, and cardiovascular disease affect millions of people living with diabetes. For years, researchers focused on inflammation, oxidative stress, and poor circulation to explain these complications. …

For years, diabetic kidney disease (DKD) has been viewed as a single condition that progresses in a fairly predictable way. However, new research suggests that this assumption may overlook important biological differences between patients. Scientists have now identified a previously hidden subtype of diabetic kidney disease marked by increased B-cell …

For many people living with type 2 diabetes, the biggest challenge is not finding an effective medication. It is being able to afford it. That reality may begin to change now that the U.S. Food and Drug Administration (FDA) has approved the first generic versions of Farxiga (dapagliflozin), potentially making …

For years, the treatment of diabetic kidney disease focused primarily on glycemic control and blood pressure management. More recently, SGLT2 inhibitors and GLP-1 receptor agonists have transformed the landscape by reducing kidney disease progression and cardiovascular events. However, another therapeutic class is rapidly gaining recognition. Non-steroidal mineralocorticoid receptor antagonists (MRAs) …

The concept of CKM staging in primary care has gained attention as clinicians look for better ways to manage the growing overlap between cardiovascular disease, kidney disease, diabetes, and metabolic disorders. However, many providers still wonder how to translate the CKM framework into daily clinical practice. Think of CKM staging …